Hypertension and other morbidities with Cushing’s syndrome associated with corticosteroids: a review

Melpomeni Peppa1, Maria Krania1, Sotirios A Raptis2,31Endocrine Unit, 2Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, Athens University Medical School, Attikon University Hospital, Athens, Greece; 3Hellenic National Diabetes Center for the Prevention, Re...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Melpomeni Peppa (Yazar), Maria Krania (Yazar), Sotirios A Raptis (Yazar)
Materyal Türü: Kitap
Baskı/Yayın Bilgisi: Dove Medical Press, 2011-03-01T00:00:00Z.
Konular:
Online Erişim:Connect to this object online.
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2bf20c1df3d742f9b339e201c9a6eadc
042 |a dc 
100 1 0 |a Melpomeni Peppa  |e author 
700 1 0 |a Maria Krania  |e author 
700 1 0 |a Sotirios A Raptis  |e author 
245 0 0 |a Hypertension and other morbidities with Cushing’s syndrome associated with corticosteroids: a review 
260 |b Dove Medical Press,   |c 2011-03-01T00:00:00Z. 
500 |a 1178-7104 
520 |a Melpomeni Peppa1, Maria Krania1, Sotirios A Raptis2,31Endocrine Unit, 2Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, Athens University Medical School, Attikon University Hospital, Athens, Greece; 3Hellenic National Diabetes Center for the Prevention, Research, Treatment of Diabetes and its Complications (HNDC), Athens, GreeceAbstract: Corticosteroids constitute an ideal treatment for various inflammatory and autoimmune disorders due to their anti-inflammatory and immunomodulatory actions. However, corticosteroids have a considerable number of side effects, including hypertension, diabetes, lipid disorders, sleep apnea, osteoporosis, myopathy, and disorders of coagulation and fibrinolysis, which are components of Cushing’s syndrome (CS). Corticosteroid-induced side effects are dependent on the formulation, route, dose, and time of exposure. However, the underlying pathogenetic mechanisms have not been clearly defined. A large body of evidence supports the role of an imbalance between vasoconstriction and vasodilation with possible links to nitric oxide, prostanoids, angiotensin II, arginine vasopressin, endothelins, catecholamines, neuropeptide Y, and atrial natriuretic peptide. Increased oxidative stress, renin–angiotensin system activation, increased pressor response, metabolic syndrome, and sleep apnea appear to be pathogenetically involved as well. The ideal treatment is the withdrawal of corticosteroids, which is most often impossible due to the exacerbation of the underlying disease. Alternatively, a careful plan, including the proper selection of the formulation, time, and route, should be made, and each side effect should be treated properly. The focus of the research should be to develop synthetic corticosteroids with anti-inflammatory effects but fewer metabolic effects, which so far has been unsuccessful.Keywords: corticosteroids, hypertension, iatrogenic Cushing’s syndrome 
546 |a EN 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Integrated Blood Pressure Control, Vol 2011, Iss default, Pp 7-16 (2011) 
787 0 |n http://www.dovepress.com/hypertension-and-other-morbidities-with-cushingrsquos-syndrome-associa-a6541 
787 0 |n https://doaj.org/toc/1178-7104 
856 4 1 |u https://doaj.org/article/2bf20c1df3d742f9b339e201c9a6eadc  |z Connect to this object online.